Podcasts about ttr

This episode of Don't Miss a Beat centers on the evolving treatment landscape for transthyretin amyloid cardiomyopathy (ATTR-CM) with special guest Ahmad Masri, MD. Hosts Muthiah Vaduganathan, MD, MPH, a cardiologist and codirector of the Center for Cardiometabolic Implementation Science at Brigham and Women's Hospital, and Steve Greene, MD, an advanced heart failure specialist at Duke University School of Medicine, are joined by Masri, who serves as the director of the HCM and Amyloid Program at Oregon Health & Science University, to discuss the rapid therapeutic advances in ATTR-CM and the emerging questions shaping real-world clinical practice. Masri reviews the progression from a previously untreatable disease to one now managed with three US Food and Drug Administration (FDA)-approved disease-modifying agents: tafamidis (VYNDAMAX), acoramidis (Attruby), and vutrisiran (AMVUTTRA). He highlights the tafamidis approval in 2019 as a landmark in the field, showing a substantial survival benefit in the ATTR-ACT trial, followed by similar results from acoramidis, which received approval in late 2024, in ATTRibute-CM. Vutrisiran, a TTR gene silencer approved by the FDA in March 2025, represents a mechanistically distinct approach validated in the HELIOS-B trial. Despite these advances, Masri notes that patients with late-stage disease derive limited symptomatic benefit and that residual risk remains high, even with treatment. The conversation explores whether stabilizers and silencers can or should be combined, with Masri urging caution, citing the absence of clinical data demonstrating additive benefit and warning against assumptions of harmony without clinical evidence. Masri indicated ongoing trials, such as CARDIO-TTRansform, may offer clarity on this issue. Without direct comparisons between therapies, treatment selection often hinges on patient preference, delivery method, pill burden, and payer coverage. In practice, clinicians rely on pharmacodynamic markers, like changes in TTR levels, to assess treatment effect and adjust therapy accordingly. Masri emphasizes that while ATTR-CM trials may not show improvements in quality-of-life scores, slowing disease progression remains a critical and meaningful endpoint in this severe, high-mortality condition. Looking ahead, the panel discusses the next wave of therapeutic innovation. Multiple trials are now testing agents that aim to clear amyloid from the myocardium, including NI006 (ALXN2220), PRX004, and AT-02. These immune-modulating treatments are designed for long-term use and may complement stabilizers or silencers in patients with established amyloid burden. The episode closes with a discussion on prevention. For patients with asymptomatic cardiac involvement, current therapies halt disease progression entirely in many cases. For those with pathogenic TTR variants but no overt disease, surveillance is the current standard. However, Masri introduces the ACT Early trial, which will test whether early treatment with acoramidis can prevent the onset of clinical disease in high-risk individuals, potentially reshaping the paradigm of ATTR-CM care. Relevant disclosures for Vaduganathan include Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others. Relevant disclosures for Greene include Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others. Key Episode Timestamps 00:00:00 Introduction and Guest Introduction 00:00:52 Current State of Amyloid Therapeutics 00:03:41 Introduction of New Stabilizers and Silencers 00:06:05 Combination Therapy and Clinical Data 00:10:36 Choosing Therapy for Patients 00:16:40 Disease Progression and Clinical Trials 00:20:28 Pipeline and Future Therapies 00:23:51 Preventative Therapy and Asymptomatic Patients 00:27:19 Conclusion and Future Directions

Tom Rogers is joined live by Catherine McKinnell MP to discuss latest government policy on the apprenticeships for teachers policy. The programme will now run over 9 months instead of 12. The government hopes this will lead to more schools offering the programme as it can be run over one academic year. Will this reduce rigour? We ask the questions in this TTR special interview. 

Join Tony Harwood, Science teacher, for his debut show on TTR. He is joined by fellow teacher Yannick to discuss what it is like to teach in a challenging school and so much more! 

In her first ever TTR show, Huma talks about leadership across borders - in various international contexts. She is joined by guest Dr George Scorgie, the Dean of Student Activities at Robert College, Istanbul.

Michelle Hinds is joined by John Catt author and fellow TTR host Morgan Whitfield to discuss her new book 'Gifted? The shift to enrichment, challenge and equity'. Michelle and Morgan explore what giftedness truly means, looking at practical solutions to stretch and challenge students of all abilities and ways to overcome the barriers to equity. Circus themed chapters set the foundation for engaging, relevant and enlightening discussions framed by historical background information. You can get a copy of Morgan's book here. Use the code JCTTR2425 for 20% off at the checkout. 

Philip's journey with ATTR began with unexplained weight loss and gastrointestinal issues that puzzled doctors for years. Despite seeing multiple specialists, his condition remained undiagnosed until a physician at Johns Hopkins finally connected the dots, confirming ATTR. By then, Philip had lost 60 pounds and was on the brink of survival. In today's episode of On Rare, David Rintell, Head of Patient Advocacy at BridgeBio, and Mandy Rohrig, Senior Director of Patient Advocacy at BridgeBio Gene Therapy, speak with Philip and his wife, Sally, who has helped to navigate the frustrating medical system, advocate for answers, and ultimately helped Philip receive life-saving IV nutrition. After years of uncertainty, Philip finally found an expert team with the knowledge, treatment, and community they needed. Philip and Sally share their story of perseverance, partnership, and hope for a brighter future. Dr. Adam Castaño, head of the Amyloid Prevention Program at BridgeBio, provides a medical overview of TTR amyloidosis (ATTR), a rare, progressive disease caused by misfolded transthyretin (TTR) proteins that form amyloid deposits in different parts of the body such as the heart, the peripheral nervous system, and the gastrointestinal tract. These deposits lead to debilitating symptoms including heart failure, neuropathy, and digestive issues, often mimicking common age-related conditions and possibly contributing to underdiagnosis. ATTR can be hereditary, but it also develops in the general population (this is called wild type). Advancements in non-invasive imaging and specialized protein staining have improved early detection, offering hope for better disease management.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The CDC has rescheduled a vaccine meeting for April, while President Trump is considering Texas Republican Michael Burgess as the new director of the agency. J&J's Tremfya has won approval for expansion in treating Crohn's disease, while Adaptimmune is facing financial uncertainty despite sales of its T cell therapy. Alnylam's Amvuttra has been approved as the first RNAi silencer for a rare type of cardiomyopathy, setting up competition with Pfizer and BridgeBio. Sino Biological has developed reagents for the 2025-2026 influenza vaccine strains. In other news, J&J plans to boost US manufacturing following tariff threats, Novartis' Fabhata has been approved as the first therapy for a rare kidney disease, and Sanofi commits up to $1.9 billion for Dren Bio's bispecific antibody for autoimmune diseases. Paratek has acquired Optinose for up to $330 million, Purdue Pharma has filed for bankruptcy again to support an opioid settlement, and Novartis' Zolgensma has been found effective in older children.The FDA has approved Alnylam's Amvuttra as the first RNAi silencer for a rare type of cardiovascular disease called ATTR-CM, following the approval of BridgeBio's Attruzy for the same condition. This approval has sparked a three-way race in the rapidly expanding space, with Pfizer's Tafamidis also in the competition. Alnylam is optimistic about Amvuttra's unique mechanism of action, which targets the disease at its source by rapidly reducing the disease-causing TTR protein. This approval comes after Attruzy was also approved for polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in June 2022. This development has brought cardiovascular disease back into the spotlight, with other companies launching new drugs and treatments for various heart conditions.

CardioNerds Cardiac Amyloidosis Series Chair Dr. Rick Ferraro and Episode Lead Dr. Anna Radakrishnan discuss the biology of transthyretin amyloid cardiomyopathy (ATTR-CM ) with Dr. Daniel Judge.  Notes were drafted by Dr. Anna Radakrishnan. The audio was engineered by student Dr. Julia Marques.  This episode provides a comprehensive overview of transthyretin (ATTR) cardiac amyloidosis, a complex and rapidly evolving disease process. The discussion covers the key red flags for cardiac amyloidosis, the diagnostic pathway, and the implications of hereditary versus wild-type ATTR. Importantly, the episode delves into the current and emerging therapies for ATTR, including stabilizers, gene silencers, and promising treatments like CRISPR-Cas9 and antibody-based approaches. Dr. Judge shares his insights and excitement about the rapidly advancing field, highlighting the need for early diagnosis and the potential to improve long-term outcomes for patients with this condition.  Enjoy this Circulation Paths to Discovery article to learn more about the CardioNerds mission and journey.  US Cardiology Review is now the official journal of CardioNerds! Submit your manuscripts here.  CardioNerds Cardiac Amyloid PageCardioNerds Episode Page Pearls: - Biology of Transthyretin amyloid cardiomyopathy Maintain a high index of suspicion! Look for subtle (yet telling) signs like ventricular hypertrophy, discordant EKG findings, bilateral carpal tunnel syndrome, and spontaneous biceps tendon rupture.  Utilize the right diagnostic tests. Endomyocardial biopsy remains the gold standard, but non-invasive tools like PYP scan with SPECT imaging and genetic testing are essential for accurate diagnosis.  Differentiating hereditary from wild-type ATTR is critical, as genetic forms may have a more aggressive course and familial implications.  Early diagnosis and intervention significantly improve prognosis, making vigilance in screening and prompt treatment initiation essential.  The future is now! Cutting-edge therapies are transforming the treatment landscape, including TTR stabilizers, gene silencers, and emerging technologies like CRISPR-Cas9 and antibody-based treatments.  Notes - Biology of Transthyretin amyloid cardiomyopathy What is transthyretin amyloid (aTTR) and how is it derived?  Transthyretin (TTR) is a transport protein primarily synthesized by the liver, responsible for carrying thyroid hormones (thyroxine) and retinol (vitamin A) in the blood. It circulates as a tetramer, composed of four identical monomers, which is essential for its stability and function.  In transthyretin amyloid (ATTR) amyloidosis, the TTR protein becomes unstable, leading to its dissociation into monomers. These monomers misfold and aggregate into insoluble amyloid fibrils, which deposit extracellularly in tissues such as the heart, nerves, and gastrointestinal tract. This progressive amyloid deposition leads to organ dysfunction, including restrictive cardiomyopathy and neuropathy.  There are two main forms of ATTR amyloidosis: hereditary (variant) and wild-type (senile) ATTR.  Hereditary ATTR (ATTRv) is caused by mutations in the TTR gene. These mutations destabilize the TTR tetramer, making it more prone to dissociation. This increases misfolding and amyloid fibril formation, resulting in systemic amyloid deposition.   Wild-type ATTR (ATTRwt) occurs without genetic mutations and is primarily age-related. Over time, even normal TTR tetramers can become unstable, leading to gradual misfolding and amyloid deposition, particularly in the heart. ATTRwt is a common but often underdiagnosed cause of heart failure with preserved ejection fraction (HFpEF) in elderly individuals.  How does aTTR lead to deleterious effects in the heart and other organ systems?    Transthyretin amyloidosis leads to organ dysfunction through the deposition of misfolded TTR protein as amyloid fib...

On This Episode of the Defending The Edge Podcast with DefendEdge, the team talks about how AI could be used to predict earthquakes, ransomware groups decreasing their TTR, Black Basta's internal conflicts being shared with the threat intelligence community and more. 

In this episode Ben White, school leader, research enthusiast and education writer is joined by Dan Boorman in his TTR series ‘Classroom Chronicles' which explores this theme with teachers and school leaders from across our schools.

Welcome back to another episode of the 360 Money Matters Podcast!    In this episode, we discuss strategies for saving tax as you approach retirement, focusing on the Transition to Retirement (TTR) strategy. We explain how individuals can take advantage of tax arbitrage opportunities by utilizing superannuation rules. Key points include the use of two superannuation accounts—accumulation and pension—to optimize income and legally reduce tax obligations. We also explore how salary sacrificing into superannuation while drawing from a pension account can create significant tax savings, potentially amounting to tens of thousands of dollars annually.   Discover how to save thousands in taxes before retirement—tune in now to learn about the Transition to Retirement strategy and maximize your superannuation benefits! - This podcast contains information that is general in nature. It does not take into account the objectives, financial situation, or needs of any particular person. You need to consider your financial situation and needs before making any decisions based on this information. This information is provided by Billy Amiridis &  Andrew Nicolaou of 360 Financial Strategists Pty Ltd, authorized representatives and credit representatives of AMP Financial Planning – AFSL 232706   Episode Highlights About the transition to retirement strategy Mechanics of TTR strategy Tax benefits of TTR Contribution and withdrawal limits The complexities involved in managing TTR strategies and the importance of professional advice Connect with Billy and Andrew! 360 Financial Strategists    Check out our latest episode here:  Apple Podcast Spotify

This week John Gibbs revisits his show over the past year and asks: what have I learned? With the help of guests Dennis Sherwood, Dr Edda Sant, Professor Ester Leslie, PhD researcher Hannah Robinson as well as fellow TTR hosts Brent Poland, Lucy Neuburger, and Paul Hazzard, John explores lessons including: The (un)reliability of exams The instrumentalism creeping into schools. Educating for democracy Loss of teacher autonomy How teachers use humour Embrassing mess    

Disciples!! Here it is – TTR 1982 Part 2 is here, and the final for 1982. 40 great tracks, hand-selected by yours truly, and of course a bonus ‘demo’ track from an important Thrash Metal band who’s NOT in the ‘Big 4’. Enjoy, and do so at a loud volume.m/ BLOCK ONE: 0:00:00 TTR Intro0:01:00 … … Continue reading →

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/management-of-amyloid-cardiomyopathy-and-polyneuropathy-9813SummaryIn this CME/CE podcast episode, Cardiologist Dr. Michelle Kittleson and Neurologist Dr. Chafic Karam discuss the multidisciplinary management of transthyretin amyloidosis (ATTR). They explore how ATTR affects both the heart and the nervous system, focusing on recognizing symptoms, diagnosing the disease, and managing treatment. Dr. Karam shares insights on peripheral neuropathy caused by amyloidosis, including clues that suggest amyloidosis over more common neuropathies. Dr. Kittleson highlights how cardiologists assess and manage TTR cardiomyopathy, emphasizing the importance of early diagnosis and the evolving therapeutic landscape. Together, they discuss the collaborative nature of care, the impact of new therapies on clinical outcomes, and the importance of raising awareness for ATTR.Learning ObjectivesDescribe the correct diagnostic algorithm for suspected ATTR, including interpretation of the monoclonal protein screen and indications for biopsy and genetic testingInitiate appropriate management, including disease-directed therapy and appropriate cardiac care, or referral when indicatedThis activity is accredited for CME/CE CreditAssociation of Black Cardiologists, Inc. (ABC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Association of Black Cardiologists, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and ABC. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.25 contact hours (which does not include hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Summary of Individual DisclosuresPlease review faculty and planner disclosures here.Disclosure of Commercial SupportThis educational activity is supported by an educational grant from Alnylam Pharmaceuticals Inc., and an educational grant from AstraZeneca Pharmaceuticals.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Ce 11 novembre est le bienvenu pour souffler un peu. Mais au fait, comment s'accorder du temps de repos supplémentaire ? Pourquoi ne pas opter pour les TTR, les fameux temps de trajet responsable ? Les explications d'Emilie Chaussier, journaliste. Ecorama du 11 novembre 2024 présenté par David Jacquot sur Boursorama.com Hébergé par Audion. Visitez https://www.audion.fm/fr/privacy-policy pour plus d'informations.

Disciples!! It feels like it’s been forever, even though it’s only been about a month and a half. It’s Time Travel Radio 1982!! For this series, there’ll be only two episodes for this year, but I did add a few more tracks to each episode. So, without further ado, TTR 1982 P1. m/ (file corrected … Continue reading (346) Time Travel Radio 1982 P1 (fixed) →

Offrir des jours de congés aux salariés quand ils et elles voyagent de façon plus éco-responsable. Une drôle d'idée pourtant déjà concrète. C'est l'entreprise Ubiq qui a ouvert la voie en France, la première à avoir mis en place un tel système. La société est spécialisée dans les solutions de bureaux en France.  Depuis janvier 2023, elle a mis en place le concept du TTR - le Temps de trajet responsable. Désormais, les salariés peuvent bénéficier de deux jours de congés supplémentaires par an, lorsqu'ils partent en voyage de façon plus respectueuse de l'écologie. Qu'est-ce que le temps de trajet responsable ? Comment ça marche ? Est-ce un geste principalement symbolique ? Écoutez la suite de cet épisode de "Maintenant vous savez". Un podcast Bababam Originals, écrit et réalisé par Johanna Cincinatis. Première diffusion : 3 mai 2023 À écouter aussi : Les plantes communiquent-elles vraiment entre elles ? Qu'est-ce que le néo-luddisme, ce mouvement qui traverse les époques ? Pourquoi la fin du ticket de caisse en France fait-elle débat ? Retrouvez tous les épisodes de "Maintenant vous savez". Suivez Bababam sur Instagram. Learn more about your ad choices. Visit megaphone.fm/adchoices

In her debut TTR show, Dani discussed top tips for leaders, reflects on past mistakes and answers questions about how leaders can navigate tricky situations! Dani gives 5 top tips: 1. You don't have to know it all! 2. Listen. 3. Lead by example. 4. You can't / shouldn't change everything in one go. 5. Protect your people.

Ben Vinton is the founder of Iso-Alpha, a nootropic brand focused on brain health. With an MBA and a background at Amazon retail, Ben moved into the health and wellness space about four years ago as a nutrition coach. He then started his own supplement brand, leading to the creation of Iso-Alpha one year ago.   A father of six, including three stepchildren, Ben lives in Utah, where he enjoys the outdoors and staying fit. His work with experts like Dr. Eric Khurts ensures Iso-Alpha remains at the cutting edge of science. Ben is passionate about spreading education on the potential benefits of Iso-Alpha, dedicated to enhancing mental performance and overall wellness.   Iso Alpha Website: Use Code ITP for discount https://isoalpha.com/   Medical Studies on Iso Alpha:  https://isoalpha.com/pages/medical-studies   From Ben:   Lastly I dove into one of the antimicrobial studies with Matured Hops Bitter Acids and wanted to provide some additional notes as I didn't have a clear answer for you on the show:   Antimicrobial Properties of Trans-Isohumulones (Trans-Ishoumulones are a specific type of isomerized alpha acids, modified further to enhance stability and are part of the Isohumulone complex in Iso-Alpha) Research indicates that trans-isohumulones, compounds derived from hops, exhibit significant antibacterial activity. These compounds work by: Inhibiting Harmful Bacteria: Trans-isohumulones are particularly effective against bacteria like Lactobacillus brevis. Enhancing Gut Health: By reducing harmful bacteria, they help maintain a balanced gut microbiome, which is crucial for digestion and overall health. Mechanism of Action The effectiveness of trans-isohumulones is influenced by environmental factors such as pH levels and the presence of specific ions: pH Levels: Their antibacterial activity increases in lower pH environments, where they remain undissociated and most effective. Ions: The presence of monovalent cations (like potassium and sodium) enhances their activity, while divalent cations (like magnesium) can reduce it.   Work With Me: Mineral Balancing HTMA Consultation: https://www.integrativethoughts.com/category/all-products  My Instagram: @integrativematt My Website: Integrativethoughts.com   Advertisements:   Viva Rays: Use Code ITP for a Discount https://vivarays.com/   Zeolite Labs Zeocharge: Use Code ITP for 10% off https://www.zeolitelabs.com/product-page/zeocharge?ref=ITP Magnesium Breakthrough: Use Code integrativethoughts10 for 10% OFF https://bioptimizers.com/shop/products/magnesium-breakthrough Just Thrive: Use Code ITP15 for 15% off https://justthrivehealth.com/discount/ITP15 Therasage: Use Code Coffman10 for 10% off https://www.therasage.com/discount/COFFMAN10?rfsn=6763480.4aed7f&utm_source=refersion&utm_medium=affiliate&utm_campaign=6763480.4aed7f   Chapters: 00:00 Introduction and Background 05:14 ISO Alpha: An Extract from Hops 09:21 The Benefits of ISO Alpha 14:31 The Subtle and Calming Effects of ISO Alpha 20:53 Studies on ISO Alpha 28:29 Introduction to Iso-Alpha and its Benefits 37:14 Iso-Alpha and Gut Health 46:50 Stimulating Brown Fat with Iso-Alpha 53:28 Conclusion and Future Research on Iso-Alpha   Takeaways: ISO Alpha is a brain health supplement made from an extract of hops called isohumulones. The product activates the vagus nerve and modulates dopamine release, leading to improved mood, focus, and mental clarity. ISO Alpha increases TTR protein levels, which help remove amyloid betas and plaque buildup in the brain, potentially reducing the risk of Alzheimer's. The benefits of ISO Alpha may be noticed after 60-90 days of use, and it offers a subtle and calming effect. Iso-Alpha is a natural compound derived from hops that has neuroprotective effects and reduces insulin resistance. It stimulates the vagus nerve and has potential benefits for cognitive function, weight management, and gut health. While there are no specific studies on its effects on conditions like autism or ADHD, Iso-Alpha may have positive effects in these areas. More research is needed to fully understand the potential of Iso-Alpha, but it shows promise as a natural and effective supplement.   Keywords: brain health, ISO Alpha, hops extract, isohumulones, neuroprotective, cognitive benefits, vagus nerve, dopamine release, mood, focus, mental clarity, TTR protein, amyloid betas, plaque buildup, Alzheimer's, iso-alpha, hops, neuroprotective, insulin resistance, vagus nerve, cognitive function, weight management, gut health, autism, ADHD  

Disciples! Here we go! Finally kicking off TTR 1981 with episode 333 – half the beast! There’s some great obvious bands as well as some ‘lesser-knowns’ and here’s where we start. Enough talking – let’s get rockin’! m/ (Time) Artist – Song [Album]BLOCK ONE: 0:01:00 The Tubes – Talk To Ya Later [The Completion Backward … Continue reading (333) Time Travel Radio 1981 Pt.1 →

Join Alex for his debut show on TTR as he talks to special guest Thabo Miles-Matli about the current teacher recruitment crisis and how it might be resolved. Thabo is a Senior Lecturer of Computer Science Education at the Faculty of Social Sciences and Social Professions, London Metropolitan University.

Join us for a special live episode presented by Salomon at Vo2 Sports Co. in Collingwood, Ontario. This panel discussion, "How to Bring More Women to Trail Running," features insights from four inspiring women: Erin Doucette, Sabrine Chanda, Christina Blackley, and moderator Molly Hurford. Discover strategies and stories to inspire more women to hit the trails, and delve into the complex factors that limit access to running for different people. Don't miss this empowering conversation!   This Episode is brought to you by Consummate Athlete Event and Goal Based Training Plans, available in the Training Peaks Store. This ready to go plans are available to start whenever you are and provide a valuable and proven workouts to guide you to your goal or event. Use Code ‘CAPOD' to get 25% of any of the plans . bit.ly/PGPLANS Download  Find links to your favorite Podcast App (remember to rate and review!) https://pod.link/1100471297   Watch The Consummate Athlete Podcast on Youtube HERE Show Notes Erin Doucette is a workplace disability and injured worker advocate, mother, run lead for TTR and founder of The Trail Collective Sabrine Chanda, athlete, Arc'teryx staff, advocate for inclusion and disability awareness Christina Blackley, an athletic individual, played sports from soccer to flag football, Illustrator, and run lead for Barrie Run Ninjas Vo2 Sports Co. Solomon    Consummate Athlete Event and Goal Based Training Plans, available in the Training Peaks Store. Use Code ‘CAPOD' to get 25% of any of the plans . bit.ly/PGPLANS   SUPPORT THE SHOW Use this link to support the show (for free!) while you shop: https://amzn.to/3Aej4jl This episode is brought to you by 3 Month 100% Made for You Training Plans by Consummate Athlete – These popular plans are made from scratch for you to fit your goals, your schedule, your gear, and your goals. https://consummateathlete.com/training-plans/   Connect with Molly & Peter Subscribe to our Newsletter Book a Consultation – https://calendly.com/smartathlete Books By Molly Hurford https://amzn.to/3bOztkN Get The Consummate Athlete Book Follow The Consummate Athlete on Instagram and Facebook Follow Molly Hurford on Instagram Follow @PeterGlassford on Instagram Consummate Athlete Links for Coaching and other services   Past guests: Stacy Sims, Stephen Seiler, Simon Marshall, Frank Overton, Dean Golich, Joe Friel, Marco Altini Katerina Nash, Kelly Starrett, Geoff Kabush, Ellen Noble, Phil Gaimon, David Roche, Matt Fitzgerald, Dr. Marc Bubbs, Christopher McDougall, Rebecca Rusch, Kate Courtney, David Epstein Kelly Starrett, Juliet Starrett, and many more

Sean joins David Rintell, Head of Patient Advocacy at BridgeBio, and Mandy Rohrig, Director of Patient Advocacy at BridgeBio Gene Therapy to share his journey with ATTR. In this episode, Sean describes his initial symptoms, which included carpal tunnel syndrome and numbness in his foot and ankle, the misdiagnosis he experienced, and his eventual diagnosis at the Cleveland Clinic in Abu Dhabi. While the diagnosis was a relief it was also difficult to accept and took an emotional toll on him and those around him. Sean has found this to be a common experience of many diagnosed with ATTR. Since Sean's form of ATTR is hereditary, various members of his family have also been tested. Sean also highlights the positive changes in his life, including meeting his wife, Robin, discovering a talent for drawing, and becoming a public speaker about ATTR. Jonathan Fox, President and Chief Medical Officer of cardiorenal programs at BridgeBio, joins us again to give a medical introduction to ATTR. On this episode, Jonathan highlights the differences of the ATTR T80 variant. Previously, we learned that ATTR amyloidosis is caused by the dissociation of a protein called transthyretin, or TTR, that changes its shape and forms into fibrous clumps. These clumps of misshapen protein are deposited into various organs and peripheral nerves, including the heart, which can cause them to function abnormally. Jonathan explains the possible origin of the T80 variant and how the T80 variant symptoms can differ from ATTR-CM.   To learn more about living with amyloidosis visit Mackenzie's Mission, www.mm713.org

WOW Divine Guidance at it's BEST! On the Show I will reveal to you My own personal unfolding of this amazing opportunity! SPIRIT is so amazing and full of Love for each of US! So many things to unpack about this show... Let me start with about a year or so agoo I contacted The TTR execs with an idea to see if I could promote some of the Amazing Hosts that Bring it for our audiences every Show. I think it was also to celebrate Dr. Pat and what she has created for each of us as Hosts and how doing our SHows on TTR has completely changed our Lives. [ Dr Pat you beautiful SOUL - if you are reading this I still feel that way - oh and the idea still brings joy to my being - wink wink- So... Yes! Peggy IS one of TTRS amazing Hosts and she is going to be on here with me. And... Peggy is bringing forward a unique opprtunity to me and possibly YOU - to join in the experience of being an author in her latest Book "Wellness GPS" This boom is the 3rd of her Wellness Series - The last one went to the Best Seller list!!! 2000 beautiful flowing words on YOUR take on Wellness Get Prepared for Success! I am so excited!! Mine part in the book of course will be about SPIRIT and... you will have to find out when it comes out! There are 10 spots left in this amazing opportunity - so I pulled Peggy on here to share all about it - incase one of you my awesome listeners are to have this experience with me! The beautiy of opportunities like this is Sharting them! Worthiness is a currency all in Oneness share . So honestly at this time I had to really push my doubts and worries of physical monies aside and say I AM Worthy of this experince and I am going to Go For IT! You cannot write the things that your Soul and the Universe brings forward [No pun intended] many times it comes right smack in a space that is the very opposite of your reality.. That's the FUN part.. So many Divine things come to break the shell of unwortiness and crack the Qhuantum Fields of BEING ALL that you are. Peggy is a bundle of Energetic vibes of Wellness and she is here to share this amazing experience with US! Watch Here: https://youtu.be/gYQgIQK0syo

For the Anime Fans of the world, hearing the big three brings three fantastic shows to mind that have shaped modern anime. In the Hobby Board Game world, the big three include: Settlers of Catan, Carcassone, and today's classic Ticket To Ride. TTR is a drafting placement game where players are creating train routes across North America to get the most points. An iconic staple of the BG world, what do our bards think of it?? You'll have to watch to find out!You can find Ticket to Ride for yourself at:https://amzn.to/3UFvBJOJason and Robbie have the goal of introducing non-gamers to the amazing world of tabletop gaming. With over 35 years of modern board gaming experience, we strive to open newer gamers to a variety of games that may be fun and exciting for them.  Whether it's the theme, mechanics, or length of the game, we hope to demystify the negative stigma that often accompanies tabletop gaming and help players realize the tabletop gaming world is for everyone!We hope you accompany us on this journey … and join us at the table!Be sure to follow us on Instagram as well!https://www.instagram.com/bards_of_the_board/Chapters:0:00 Intro4:00 What We've Been Playing26:00 Ticket to Ride54:30 Cookie Scale1:03:30 Final Thoughts

With its potential to expand the horizons of what's possible for patients, CRISPR is the new darling of biotech. Reaching an important milestone in 2023 with the FDA approval of a sickle cell treatment using CRISPR, the technology is poised to break new barriers for treating patients in the near future. In this episode we talk with two companies working together on the next generation of CRISPR: editing cells within the body.  We discuss the progress and the challenge in making this breakthrough a reality. Follow us on LinkedIn, X, Facebook and Instagram. Visit us at https://www.bio.org/

In this episode, we reveal a SPX weekly options strategy selling put credit spreads that expire the following day. This strategy uses bullish TTR readings from Alpha Crunching to determine whether or not to take the trade that day. Today's episode is from a video training recently sent to Alpha Crunching subscribers and posted in the free community. Here's the link to watch the 10m video presentation of this strategy:https://www.stockmarketoptionstrading.net/posts/55173187The TTR is a metric from https://www.alphacrunching.com that shows the tendency for the next day to close higher from the current day. TTR stands for Tomorrow's Triumph rate. Use code SPX50 at https://www.alphacrunching.com for 50% off your first month. Want to connect with myself? Find me on LinkedIn:Eric O'Rourke: https://www.linkedin.com/in/jericorourke/After that, join other listeners at https://StockMarketOptionsTrading.net and join the community for free right now where there are daily posts with clues to the where the market may be headed next. Also, Alpha Traders Club is where I host my SPX Live Chat each day for trading SPX weekly options. We focus on the premarket data and levels, technical analysis, and options flow for trading high probability trades for weekly income. Alpha Traders Club also posts Conservative Covered Call trades each week for generating weekly and monthly income trading options on high quality stocks and ETFs. Here's the link: https://www.stockmarketoptionstrading.net/spaces/12282222Disclaimer: This podcast is for informational and educational purposes only and should not be considered financial advice.

Decision Space is the podcast about decisions in board games. Nominate Decision Space for a Golden Geek Here: https://boardgamegeek.com/geekawards/boardgame (If you have any questions or difficulty, please reach out in the discord!) Join our active and welcoming Discord community, Join the crew today! (Decision Space Patreon), or Leave us a review wherever you found this podcast! Episode 164 - Ticket To Ride with Bill Collins This week we are joined by Bill Collins. You may know him as Varianor on the Decision Space Discord. In this episode, Bill, Jake, & Brendan dive deep into the decisions in this new classic family board game. We look deep at all possible actions, the timing puzzle, the implications of no hand limit, and much more decisional goodness. Then, Bill guides us through the high points of what is out there in the extended TTR universe of products.   Pre-Planners Quantum is on our radar, Taverns of Tiefenthal is a maybe. Give us some recs! Timestamps Golden Geek - 0:00 Episode Start  - 1:30 Ratings and Game Background - 4:14 Rules Overview  - 12:52 Deep Dive Discussion - 14:45   Music and Sound Credits Thank you to Hembree for our intro and outro music from their song Reach Out. You can listen to the full song on YouTube here: https://www.youtube.com/watch?v=gQuuRPfOyMw&list=TLGGFNH7VEDPgwgyNTA4MjAyMQ&t=3s You can find more information about Hembree at https://www.hembreemusic.com/.  Thank you to Flash Floods for use of their song Palm of Your Hand as a sting from their album Halfway to Anywhere: https://open.spotify.com/album/2fE6LrqzNDKPYWyS5evh3K?si=CCjdAGmeSnOOEui6aV3_nA Rules Overview Music:  Way Home by Tokyo Music Walker https://soundcloud.com/user-356546060​ Creative Commons — Attribution 3.0 Unported — CC BY 3.0 Free Download / Stream: https://bit.ly/tokyo-music-walker-way...​ Music promoted by Audio Library https://youtu.be/pJThZlOuDtI Contact We can be reached individually on Twitter at @jakefryd and @burnsidebh. You can also follow Decision Space on Instagram @DecisionSpacePod and talk to us there! If you prefer email, then hit us up at decisionspa@gmail.com. This information is all available along with episodes at our new website decisionspacepodcast.com. Byeee!

Eric joins David Rintell, Head of Patient Advocacy at BridgeBio and Mandy Rohrig, Director of Patient Advocacy at BridgeBio Gene Therapyin a two-part conversation to talk about his experience of living with Transthyretin Amyloidosis (ATTR). Eric was an extremely active person who enjoyed sports, riding horses and working on his 20-acre property when he began to have issues which he now attributes to ATTR. Eric's diagnostic journey took 14 years and as the disease progressed, he experienced two carpal tunnel surgeries, and several other cardiac procedures. In fact, by the time he was diagnosed, Eric could not walk the length of his home (60 feet) without getting out of breath. Four years after his diagnosis he received a heart transplant. Despite the difficulties, Eric highlights the positives of this diagnosis and how living with ATTR and engaging with the ATTR community has taught him to be intellectually curious, empathetic, grateful for the care he has received and happy to be alive.  Jonathan Fox, President and Chief Medical Officer of cardiorenal programs at BridgeBio. Jonathan explains the causes of ATTR and what happens to people living with it. ATTR amyloidosis is caused by the dissociation of a protein called transthyretin, or TTR, that changes its shape and forms into fibrous clumps. These clumps of misshapen protein are deposited into various organs and peripheral nerves, including the heart, which can cause them to function abnormally.

Join Stephen for a wonderfully meandering journey through his teaching week. He gives his tips on some tools and apps that teachers could use to make their life easier, takes us on his incredibly breezy seaside walk, shares feedback he'd had from a recent lesson observation and makes us laugh a lot too! Join Stephen for another of his unmissable TTR shows!     

Join Stephen for a wonderfully meandering journey through his teaching week. He gives his tips on some tools and apps that teachers could use to make their life easier, takes us on his canal walk, shares feedback he'd had from a recent lesson observation and makes us laugh a lot too! Join Stephen for another of his unmissable TTR shows! 

Celebrating 2 years and 99 hours of TTR shows, Graham looks back on the guests and shows that featured or were dedicated to Artificial Intelligence. These range from a show in July 2022, pre-dating the explosion in generative AI, to guests such as Paul Raine in Japan, Kalyan Chattopadhyay from India, Joshua Underwood in Spain, and Chris Temple Murray from the UK. 

Visit nascentmc.com/podcast for full show notes [free course] ChatGPT4 in medical writing and editing at learnAMAstyle.com Nascentmc.com for medical writing assistance for your CME or Medical Communications company. Eplontersen for ATTR-CM Eplontersen received FDA Fast Track designation for treating transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in adults, aiming to inhibit TTR protein production. Nivolumab for NSCLC The FDA accepted supplemental applications for nivolumab in resectable stage 2A to 3B non-small cell lung cancer (NSCLC) based on the CheckMate-77T trial showing improved survival rates. RSV Vaccine for Adults Aged 50 to 59 The FDA prioritizes review of GSK's Arexvy vaccine for RSV in adults aged 50-59 at risk of complications, expanding from its existing approval for those 60 and older. Spinal Cord Stimulation System The FDA approved Boston Scientific's WaveWriter Spinal Cord Stimulation Systems for chronic low back and leg pain treatment in non-surgery patients, based on the SOLIS trial results. OK-101 for Neuropathic Corneal Pain The FDA approved an IND application for OK-101, a first for treating neuropathic corneal pain (NCP), an Orphan disease, developed by OKYO Pharma Limited. Viz ICH Plus for Brain Bleed The FDA cleared Viz ICH Plus, an AI algorithm by Viz.ai for automating the identification and quantification of brain bleeds and structures in NCCT images. Vepdegestrant for MBC Vepdegestrant received FDA Fast Track designation for treating ER-positive/HER2-negative advanced or metastatic breast cancer in patients previously treated with endocrine therapy. VerTouch Spinal Puncture Device The FDA cleared VerTouch, a handheld imaging tool by IntuiTap Medical, designed to improve the accuracy of spinal punctures by providing a 2D image of lumbar spinal anatomy.

GLP-1s and BaroStim Neo revisited, a new drug for transthyretin amyloid CM, clopidogrel vs ASA years after PCI and stent, and statins are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. GLP-1s and Obesity, BaroStim Neo Revisited FDA Expands Label for CVRx Barostim System in HF https://www.medscape.com/viewarticle/fda-expands-label-cvrx-barostim-system-hf-2023a1000wsx JAMA Cardiology Special Communication – BDP https://jamanetwork.com/journals/jamacardiology/fullarticle/2810726 II. ATTR Cardiomyopathy ATTRibute-CM NEJM paper https://www.nejm.org/doi/full/10.1056/NEJMoa2305434 Circulation Review of TTR https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.111.078915 ATTR-ACT (Tafadimis) https://www.nejm.org/doi/10.1056/NEJMoa1805689 III. Clopidogrel vs ASA Years After PCI Long-term Clopidogrel Has Advantages After Coronary Stenting https://www.medscape.com/viewarticle/long-term-clopidogrel-has-advantages-after-coronary-stenting-2024a10000c8 Stop DAPT Original Trial STOP DAPT at 5 Years https://doi.org/10.1016/j.jacc.2023.10.013 Network Meta-analysis of P2Y12-I vs ASA https://doi.org/10.1016/j.jcin.2022.08.009 IV. Statin Use Statin Use Remains Low for At-Risk Patients https://www.medscape.com/viewarticle/999043 Annals of Internal Medicine Observational Study https://doi.org/10.7326/M23-1915 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Over £500,000 was paid out to EIS members in personal injury claims in 2023 - with more than 40 per cent of settlements related to teachers being assaulted in the workplace.  So what's behind the rise in violent behaviour in Scottish schools? TTR's Tom Hopkins Burke spoke with Anne Keenan, the EIS's Assistant Secretary for Education and Equality, to find out more about the personal injury settlements paid out to Scottish teachers and what can be done to make schools safer for teachers and students in Scotland.

Members of the TTR team are joined by callers to decide what should be consigned to 2023's Staffroom 101.

Evan Hawkins is the lead singer and frontman for the popular band, Through The Roots from San Diego, CA. Having toured the country performing with top bands like Rebelution, Iration and Expendables, and making music for most of his life, Evan is a true entrepreneur and artist that is at the forefront of his craft. The parallels with running a band and running a team are undeniable. Success comes from a particular mindset to be the best at whatever it is you do and this conversation highlights that. JOIN THE DISCORD:https://www.patreon.com/bePatron?u=34554029PTG SHOW SPONSORS:LONE WOLF PAINTBALL: https://www.lonewolfpaintball.comHORMESIS PAINTBALL: https://hormesispaintball.com/HKARMY: https://www.hkarmy.com/TRANZFUSE: https://tranzlabs.com/?ref=PLAYTHEGAM...David Roque: CPA Assistant AHSBIZ@GMAIL.COMSupport the show

WOW Divine Guidance at it's BEST! On the Show I will reveal to you My own personal unfolding of this amazing opportunity! SPIRIT is so amazing and full of Love for each of US! So many things to unpack about this show... Let me start with about a year or so agoo I contacted The TTR execs with an idea to see if I could promote some of the Amazing Hosts that Bring it for our audiences every Show. I think it was also to celebrate Dr. Pat and what she has created for each of us as Hosts and how doing our SHows on TTR has completely changed our Lives. [ Dr Pat you beautiful SOUL - if you are reading this I still feel that way - oh and the idea still brings joy to my being - wink wink- So... Yes! Peggy IS one of TTRS amazing Hosts and she is going to be on here with me. And... Peggy is bringing forward a unique opprtunity to me and possibly YOU - to join in the experience of being an author in her latest Book "Wellness GPS" This boom is the 3rd of her Wellness Series - The last one went to the Best Seller list!!! 2000 beautiful flowing words on YOUR take on Wellness Get Prepared for Success! I am so excited!! Mine part in the book of course will be about SPIRIT and... you will have to find out when it comes out! There are 10 spots left in this amazing opportunity - so I pulled Peggy on here to share all about it - incase one of you my awesome listeners are to have this experience with me! The beautiy of opportunities like this is Sharting them! Worthiness is a currency all in Oneness share . So honestly at this time I had to really push my doubts and worries of physical monies aside and say I AM Worthy of this experince and I am going to Go For IT! You cannot write the things that your Soul and the Universe brings forward [No pun intended] many times it comes right smack in a space that is the very opposite of your reality.. That's the FUN part.. So many Divine things come to break the shell of unwortiness and crack the Qhuantum Fields of BEING ALL that you are. Peggy is a bundle of Energetic vibes of Wellness and she is here to share this amazing experience with US! Watch Here: https://youtu.be/gYQgIQK0syo

In this episode, I'll talk about how when it comes to options trading, you need more than the options probabilities to have an edge and to make money over time. We'll go through an example of using a put credit spread backtest as well as some new research from Alpha Crunching for trading them. The TTR is a new metric from https://www.alphacrunching.comUse code SPX50 for 50% your first month. Want to connect with myself and other listeners of this podcast?Go to https://StockMarketOptionsTrading.net and join the community for free right now where there are daily posts with clues to the where the market may be headed next. Want to trade with us?Check out our new group Alpha Traders Club on the website. https://www.stockmarketoptionstrading.net/spaces/12282222Disclaimer: Everything in this episode and on this podcast is for informational purposes only and should not be considered financial advice. There is substantial risk trading options if not done properly.

Oh wow did HFFS celebrate Keyforge this weekend! Sydnie and Blake talk about their Keyforge Celebrations live from the event. They share their highs and lows, twists and turns, juicy secrets, and heartfelt thanks yous. Tune in to learn all about their time at Keyforge Celebration 2023 (KFC2)! Link to the Keymander Discord: https://discord.com/invite/eAKP75zk Link to TTR's Twitch where you can watch recordings of Sydnie Stream and Blake's first game in the Alliance World's Tournament: https://www.twitch.tv/tabletoproyale If you wish to donate to HFFS here is our Patreon link:  https://www.patreon.com/hffspodcast • Please subscribe if you enjoyed  this episode, leave a review on Apple with your thoughts, and share it on your social channels. We appreciate any and all support. // If you wish to connect with us through social media @HFFSpodcast on Twitter & hffspodcast@gmail.com. Connect with Sydnie on Discord:  SCSteele#9355 // Rick on Twitter: @TKeyforger // Blake on Twitter: @blvdblake & YouTube:  https://www.youtube.com/channel/UCSgDdfWvcRbCC3l7CnvOJhg Join our Discord to talk about episodes and help shape future ones! https://discord.gg/w6vbkWF6Xh

"What would you do if you had a ring of invisibility? And the children will say, well, I would rob a bank. I would go into a shop and Steve chocolate. I would have a stigma favorite packet of crisps. I would be going in and stealing money out of my mommy's purse. I would do all this and I do not moralize with the federal budget. Yep, I will turn and I read it up on the board. And then I say well, what should you do?" Kevin Mc Arevey is the Principal of Holy Cross Boys' School in the Ardoyne area in Northern Belfast in Northern Ireland. Kevin has been a teacher in the Ardoyne area for 26 years with the last 10 as the Principal. Kevin has written a book "Think Think Respond (slow thinking) and TTR (fast thinking)". This can be purchased at the school at a price of £20. It's a big book and all proceeds go to HCBoys. Kevin is also the main protagonist in the Film documentary Young Plato - a film about hope, peace and reconciliation. https://youngplato.com You are able to stream Young Plato by renting or purchasing on Amazon, iTunes, and Google Play The Troubles, also called the Northern Ireland conflict, was a violent sectarian conflict from about 1968 to 1998 in Northern Ireland between the overwhelmingly Protestant unionists (loyalists), who desired the province to remain part of the United Kingdom, and the overwhelmingly Roman Catholic nationalists (republicans), who wanted Northern Ireland to become part of the republic of Ireland. Some 3,600 people were killed and more than 30,000 more were wounded before a peaceful solution, which involved the governments of both the United Kingdom and Ireland, was effectively reached in 1998, leading to a power-sharing arrangement in the Northern Ireland Assembly. To stay up to date, follow @SmitaTharoor on Smita Tharoor (@SmitaTharoor) / Twitter or Smita Tharoor (@smitatharoor) | Instagram and follow the podcast on your favorite streaming service.

In this episode, we'll cover a new strategy that uses the TTR from https://AlphaCrunching.com The TTR = Tomorrow's Triumph Rate which shows the historical percentage of times SPX has closed higher the next day over the past two months.This strategy is geared towards trading SPX options that expire the following day. By trading 1DTE options, 3DTE on Friday, you can avoid any PDT issues but also increase the number of high probability trades using the TTR to gain an edge in the market. More research on this strategy is coming and will be posted and updated in the Alpha Traders Club at https://www.stockmarketoptionstrading.net

The following question refers to Section 7.8 of the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.The question is asked by Stony Brook University Hospital medicine resident and CardioNerds Intern Dr. Chelsea Tweneboah, answered first by Mayo Clinic Cardiology Fellow and CardioNerds Academy Chief Dr. Teodora Donisan, and then by expert faculty Dr. Michelle Kittleson.The Decipher the Guidelines: 2022 AHA / ACC / HFSA Guideline for The Management of Heart Failure series was developed by the CardioNerds and created in collaboration with the American Heart Association and the Heart Failure Society of America. It was created by 30 trainees spanning college through advanced fellowship under the leadership of CardioNerds Cofounders Dr. Amit Goyal and Dr. Dan Ambinder, with mentorship from Dr. Anu Lala, Dr. Robert Mentz, and Dr. Nancy Sweitzer. We thank Dr. Judy Bezanson and Dr. Elliott Antman for tremendous guidance.Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. Question #29 A 69-year-old man was referred to the cardiology clinic after being found to have a reduced left ventricular ejection fraction and left ventricular hypertrophy. For the last several months he has been experiencing progressively worsening fatigue and shortness of breath while getting to the 2nd floor in his house. He has a history of bilateral carpal tunnel syndrome and chronic low back pain. He takes no medications. On exam, his heart rate is 82 bpm, blood pressure is 86/60 mmHg, O2 saturation is 97% breathing ambient air, and BMI is 29 kg/m2. He has a regular rate and rhythm with normal S1 and S2, bibasilar pulmonary rales, and 1+ pitting edema in both legs. EKG shows normal sinus rhythm with a first-degree AV delay and low voltages. Transthoracic echocardiogram shows a moderately depressed LVEF of 35-39%, severe concentric hypertrophy with a left ventricular posterior wall thickness of 1.5 cm and strain imaging showing globally reduced longitudinal strain with apical sparring. There is also biatrial enlargement and a small pericardial effusion. A pharmacologic nuclear stress test did not reveal any perfusion defects. A gammopathy panel including SPEP, UPEP, serum and urine immunofixation studies, and serum free light chains are unrevealing. A 99mTc-Pyrophosphate scan was positive with grade 3 uptake. In addition to starting diuretics, what is the next most appropriate step for managing for this patient? A Start metoprolol succinate B Start sacubitril/valsartan C Perform genetic sequencing of the TTR gene D Perform endomyocardial biopsy Answer #29 Explanation The correct answer is C – perform genetic sequencing of the TTR gene.   This patient has findings which raise suspicion for cardiac amyloidosis. There are both cardiac (low voltages on EKG and echocardiogram showing marked LVH with biatrial enlargement and small pericardial effusion as well as a characteristic strain pattern) and extra-cardiac (bilateral carpal tunnel syndrome and low back pain) features to suggest amyloidosis. The diagnosis of cardiac amyloidosis requires a high index of suspicion and most commonly occurs due to a deposition of monoclonal immunoglobulin light chains (AL-CM) or transthyretin (ATTR-CM). ATTR may cause cardiac amyloidosis as either a pathogenic variant (ATTRv) or as a wild-type protein (ATTRwt).   Patients for whom there is a clinical suspicion for cardiac amyloidosis should have screening for serum and urine monoclonal light chains with serum and urine immunofixation electrophoresis and serum free light chains (Class 1, LOE B-NR). Immunofixation electrophoresis (IFE) is preferred because serum or urine plasma electrophoresis (SPEP or UPEP) are less sensitive. Together, measurement of serum IFE, urine IFE, and serum FLC is >99% sensitive for AL amyloidosis.

WOW Divine Guidance at it's BEST! On the Show I will reveal to you My own personal unfolding of this amazing opportunity! SPIRIT is so amazing and full of Love for each of US! So many things to unpack about this show... Let me start with about a year or so agoo I contacted The TTR execs with an idea to see if I could promote some of the Amazing Hosts that Bring it for our audiences every Show. I think it was also to celebrate Dr. Pat and what she has created for each of us as Hosts and how doing our SHows on TTR has completely changed our Lives. [ Dr Pat you beautiful SOUL - if you are reading this I still feel that way - oh and the idea still brings joy to my being - wink wink- So... Yes! Peggy IS one of TTRS amazing Hosts and she is going to be on here with me. And... Peggy is bringing forward a unique opprtunity to me and possibly YOU - to join in the experience of being an author in her latest Book "Wellness GPS" This boom is the 3rd of her Wellness Series - The last one went to the Best Seller list!!! 2000 beautiful flowing words on YOUR take on Wellness Get Prepared for Success! I am so excited!! Mine part in the book of course will be about SPIRIT and... you will have to find out when it comes out! There are 10 spots left in this amazing opportunity - so I pulled Peggy on here to share all about it - incase one of you my awesome listeners are to have this experience with me! The beautiy of opportunities like this is Sharting them! Worthiness is a currency all in Oneness share . So honestly at this time I had to really push my doubts and worries of physical monies aside and say I AM Worthy of this experince and I am going to Go For IT! You cannot write the things that your Soul and the Universe brings forward [No pun intended] many times it comes right smack in a space that is the very opposite of your reality.. That's the FUN part.. So many Divine things come to break the shell of unwortiness and crack the Qhuantum Fields of BEING ALL that you are. Peggy is a bundle of Energetic vibes of Wellness and she is here to share this amazing experience with US! Watch Here: https://youtu.be/gYQgIQK0syo

Blake and Sydnie are joined this week by Justin from Tabletop Royale (TTR)! From his Keyforge origin story, to behind the scenes at TTR, to TTR's plans for the Vegas Vault Tour, listen in to hear all about these premier Keyforge streamers! Watch Justin and Nathan stream the Vegas Vault Tour LIVE this weekend: Twitch.tv/tabletoproyale Watch recordings of Justin and Nathan streaming the Vegas Vault Tour: YouTube.com/tabletoproyale BONUS Watch Andrew from 1StarPeeps5StarGames stream the Vegas Vault Tour LIVE this weekend: https://www.twitch.tv/1starpeeps5stargames If you wish to donate to HFFS here is our Patreon link:  https://www.patreon.com/hffspodcast • Please subscribe if you enjoyed  this episode, leave a review on Apple with your thoughts, and share it on your social channels. We appreciate any and all support. // If you wish to connect with us through social media @HFFSpodcast on Twitter & hffspodcast@gmail.com. Connect with Sydnie on Discord:  SCSteele#9355 // Rick on Twitter: @TKeyforger // Blake on Twitter: @blvdblake & YouTube:  https://www.youtube.com/channel/UCSgDdfWvcRbCC3l7CnvOJhg Join our Discord to talk about episodes and help shape future ones! https://discord.gg/w6vbkWF6Xh

CRISPR has emerged as a powerful tool for altering DNA sequences with incredible precision, opening up new avenues of research into the treatment of disease. In this episode, we explore the science behind CRISPR, as well as its potential. From curing genetic disorders to creating new crop varieties, the possibilities seem endless. Our four guests today are scientists working to push these gene editing tools to the next frontier.

This is Dice Tower Now for the week of May 30, 2023. This week, Asmodee goes by the numbers, CATAN continues where no one has gone before, we explore the legacy of TTR, and Lucky Duck crawls old school - on paper.   TOP STORIES (2:15) Golden Gate Gamemakers Asmodee publishes The Number by Hisashi Hayashi CATAN Starfarers New Encounters expansion Edison Award Winners announced Legacy Ticket to Ride teased by Days of Wonder CMoN to publish Emerson Matsuuchi's cancelled Metal Gear Solid title Tom Brinton's Paper Apps Dungeon being published by Lucky Duck Amritsar: The Golden Temple by David Heras Pino and Ludonova Neotopia coming from Arcane Wonders 17th Neuroshima Hex army announced - Merchants Guild New Oniverse title Cyberion coming from InPatience   SPONSOR UPDATE (14:00) Scott Morris Update and Nimalia   CROWDFUNDING (16:15) Wishland: Dreams from America 9th Circle Detective: Saints and Sinners Axe-A-Lot-L Escape: Family Box Thunder Rolls: The Garage Expansion Apex Legends the Board Game       CONNECT: Follow our Twitter newsfeed: twitter.com/dicetowernow Dig in with Corey at DiceTowerDish.com.

CRISPR has emerged as a powerful tool for altering DNA sequences with incredible precision, opening up new avenues of research into the treatment of disease. In this episode, we explore the science behind CRISPR, as well as its potential. From curing genetic disorders to creating new crop varieties, the possibilities seem endless. Our four guests today are scientists working to push these gene editing tools to the next frontier.

Original Release on February 6th, 2023: As new gene therapies are researched, developed and begin clinical trials, what hurdles must genetic medicine overcome before these therapies are commonly available? Head of U.S. Pharmaceuticals Terence Flynn and Head of U.S. Biotech Matthew Harrison discuss. ----- Transcript -----Terence Flynn: Welcome to Thoughts on the Market. I'm Terence Flynn, Head of U.S. Pharma for Morgan Stanley Research. Matthew Harrison: And I'm Matthew Harrison, Head of U.S. Biotech. Terence Flynn: And on this special episode of Thoughts on the Market, we'll be discussing the bold promise of genetic medicine. It's Monday, February 6th, at 10 a.m. in New York. Terence Flynn: 2023 marks 20 years since the completion of the Human Genome Project. The unprecedented global scientific collaboration that generated the first sequence of the human genome. The pace of research in molecular biology and human genetics has not relented since 2003, and today we're at the start of a real revolution in the practice of medicine. Matthew what exactly is genetic medicine and what's the difference between gene therapy and gene editing? Matthew Harrison: As I think about this, I think it's important to talk about context. And so as we've thought about medical developments and drug development over the last many decades, you started with pills. And then we moved into drugs from living cells. These are more complicated drugs. And now we're moving on to editing actual pieces of our genome to deliver potentially long lasting cures. And so this opens up a huge range of new treatments and new opportunities. And so in general, as we think about it, they're basically two approaches to genetic medicine. The first is called gene therapy, and the second is called gene editing. The major difference here is that in gene therapy you just deliver a snippet of a gene or pre-programmed message to the body that then allows the body to make the protein that's missing, With gene editing, instead what you do is you go in and you directly edit the genes in the person's body, potentially giving a long lasting cure to that person. So obviously two different approaches, but both could be very effective. And so, Terence, as you think about what's happening in research and development right now, you know, how long do you think it's going to be before some of these new therapies make it to market? Terence Flynn: As we think about some of the other technologies you mentioned, Matthew, those took, you know, decades in some cases to really refine them and broaden their applicability to a number of diseases. So we think the same is likely to play out here with genetic medicine, where you're likely to see an iterative approach over time as companies work to optimize different features of these technologies. So as we think about where it's focused right now, it's being primarily on the rare genetic disease side. So diseases such as hemophilia, spinal muscular atrophy and Duchenne muscular dystrophy, which affect a very small percentage of the population, but the risk benefit is very favorable for these new medicines. Now, there are currently five gene therapies approved in the U.S. and several more on the horizon in later stage development. No gene editing therapies have been approved yet, but there is one for sickle cell disease that could actually be approved next year, which would be a pretty big milestone. And the majority of the other gene editing therapies are actually in earlier stages of development. So it's likely going to be several years before those reach the market. As, again as we've seen happen time and time again in biopharma as these new therapies and new platforms are rolled out they have very broad potential. And obviously there's a lot of excitement here around these genetic medicines and thinking about where these could be applied. But I think before we go there, Matthew, obviously there are still some hurdles that needs to be addressed before we see a broader rollout here. So maybe you could touch on that for us. Matthew Harrison: You're right, there are some issues that we're still working through as we think about applying these technologies. The first one is really delivery. You obviously can't just inject some genes into the body and they'll know what to do. So you have to package them somehow. And there are a variety of techniques that are in development, whether using particles of fat to shield them or using inert viruses to send them into the body. But right now, we can't deliver to every tissue in every organ, and so that limits where you can send these medicines and how they can be effective. So there's still a lot of work to be done on delivery. And the second is when you go in and you edit a gene, even if you're very precise about where you want to edit, you might cause some what we call off target effects on the edges of where you've edited. And so there's concern about could those off target effects lead to safety issues. And then the third thing which we've touched on previously is durability. There's potentially a difference between gene therapy and gene editing, where gene editing may lead to a very long lasting cure, where different kinds of gene therapies may have longer term potential, but some may need to be redosed. Terence, as we turn back to thinking about the progress of the pipeline here, you know, what are the key catalysts you're watching over 23 and 24? Terence Flynn: You know, as everyone probably knows, biopharma is a highly regulated industry. We have the FDA, the Food and Drug Administration here in the U.S., and we have the EMA in Europe. Those are the bodies that, you know, evaluate risk benefit of every therapy that's entering clinical trials and ultimately will reach the market. So this year we're expecting much of the focus for the gene editing companies to be broadly on regulatory progress. So again, this includes completion of regulatory filings here in the U.S. and Europe for the sickle cell disease drug that I mentioned before. And then something that's known as an IND filing. So essentially what companies are required to do is file that before they conduct clinical trials in humans in the U.S. There are companies that are pursuing this for hereditary angioedema and TTR amyloidosis. Those, if successful, would allow clinical trials to be conducted here in the U.S. and include U.S. patients. The other big thing we're watching is additional clinical data related to durability of efficacy. So, I think we've seen already with some of the gene therapies for hemophilia that we have durable efficacy out to five years, which is very exciting and promising. But the question is, will that last even longer? And how to think about gene therapy relative to gene editing on the durability side. And then lastly, I'd say safety. Obviously that's important for any therapy, but given some of the hurdles still that you mentioned, Matthew, that's obviously an important focus here as we look out over the longer term and something that the companies and the regulators are going to be following pretty closely. So again, as we think about the development of the field, one of the other key questions is access to patients. And so pricing reimbursement plays a key role here for any new therapy. There are some differences here, obviously, because we're talking about cures versus traditional chronic therapies. So maybe Matthew you could elaborate on that topic. Matthew Harrison: So as you think about these genetic medicines, the ones that we've seen approved have pretty broad price ranges, anywhere from a million to a few million dollars per patient, but you're talking about a potential cure here. And as I think about many of the chronic therapies, especially the more sophisticated ones that patients take, they can cost anywhere between tens of thousands and hundreds of thousands of dollars a year. So you can see over a decade or more of use how they can actually eclipse what seems like a very high upfront price of these genetic medicines. Now, one of the issues obviously, is that the way the payers are set up is different in different parts of the world. So in Europe, for example, there are single payer systems for the patient never switches between health insurance carriers. And so therefore you can capture that value very easily. In the U.S., obviously it's a much more complicated system, many people move between payers as they switch jobs, as you change from, you know, commercial payers when you're younger to a government payer as you move into Medicare. And so there needs to be a mechanism worked out on how to spread that value out. And so I think that's one of the things that will need to evolve. But, you know, it's a very exciting time here in genetic medicine. There's significant opportunity and I think we're on the cusp of really seeing a robust expansion of this field and leading to many potential therapies in the years to come. Terence Flynn: That's great, Matthew. Thanks so much for taking the time to talk today. Matthew Harrison: Great speaking with you, Terrence. Terence Flynn: As a reminder, if you enjoy Thoughts on the Market, please take a moment to rate and review us on Apple Podcasts app. It helps more people to find the show.

As new gene therapies are researched, developed and begin clinical trials, what hurdles must genetic medicine overcome before these therapies are commonly available? Head of U.S. Pharmaceuticals Terence Flynn and Head of U.S. Biotech Matthew Harrison discuss. ----- Transcript -----Terence Flynn: Welcome to Thoughts on the Market. I'm Terence Flynn, Head of U.S. Pharma for Morgan Stanley Research. Matthew Harrison: And I'm Matthew Harrison, Head of U.S. Biotech. Terence Flynn: And on this special episode of Thoughts on the Market, we'll be discussing the bold promise of genetic medicine. It's Monday, February 6th, at 10 a.m. in New York. Terence Flynn: 2023 marks 20 years since the completion of the Human Genome Project. The unprecedented global scientific collaboration that generated the first sequence of the human genome. The pace of research in molecular biology and human genetics has not relented since 2003, and today we're at the start of a real revolution in the practice of medicine. Matthew what exactly is genetic medicine and what's the difference between gene therapy and gene editing? Matthew Harrison: As I think about this, I think it's important to talk about context. And so as we've thought about medical developments and drug development over the last many decades, you started with pills. And then we moved into drugs from living cells. These are more complicated drugs. And now we're moving on to editing actual pieces of our genome to deliver potentially long lasting cures. And so this opens up a huge range of new treatments and new opportunities. And so in general, as we think about it, they're basically two approaches to genetic medicine. The first is called gene therapy, and the second is called gene editing. The major difference here is that in gene therapy you just deliver a snippet of a gene or pre-programmed message to the body that then allows the body to make the protein that's missing, With gene editing, instead what you do is you go in and you directly edit the genes in the person's body, potentially giving a long lasting cure to that person. So obviously two different approaches, but both could be very effective. And so, Terence, as you think about what's happening in research and development right now, you know, how long do you think it's going to be before some of these new therapies make it to market? Terence Flynn: As we think about some of the other technologies you mentioned, Matthew, those took, you know, decades in some cases to really refine them and broaden their applicability to a number of diseases. So we think the same is likely to play out here with genetic medicine, where you're likely to see an iterative approach over time as companies work to optimize different features of these technologies. So as we think about where it's focused right now, it's being primarily on the rare genetic disease side. So diseases such as hemophilia, spinal muscular atrophy and Duchenne muscular dystrophy, which affect a very small percentage of the population, but the risk benefit is very favorable for these new medicines. Now, there are currently five gene therapies approved in the U.S. and several more on the horizon in later stage development. No gene editing therapies have been approved yet, but there is one for sickle cell disease that could actually be approved next year, which would be a pretty big milestone. And the majority of the other gene editing therapies are actually in earlier stages of development. So it's likely going to be several years before those reach the market. As, again as we've seen happen time and time again in biopharma as these new therapies and new platforms are rolled out they have very broad potential. And obviously there's a lot of excitement here around these genetic medicines and thinking about where these could be applied. But I think before we go there, Matthew, obviously there are still some hurdles that needs to be addressed before we see a broader rollout here. So maybe you could touch on that for us. Matthew Harrison: You're right, there are some issues that we're still working through as we think about applying these technologies. The first one is really delivery. You obviously can't just inject some genes into the body and they'll know what to do. So you have to package them somehow. And there are a variety of techniques that are in development, whether using particles of fat to shield them or using inert viruses to send them into the body. But right now, we can't deliver to every tissue in every organ, and so that limits where you can send these medicines and how they can be effective. So there's still a lot of work to be done on delivery. And the second is when you go in and you edit a gene, even if you're very precise about where you want to edit, you might cause some what we call off target effects on the edges of where you've edited. And so there's concern about could those off target effects lead to safety issues. And then the third thing which we've touched on previously is durability. There's potentially a difference between gene therapy and gene editing, where gene editing may lead to a very long lasting cure, where different kinds of gene therapies may have longer term potential, but some may need to be redosed. Terence, as we turn back to thinking about the progress of the pipeline here, you know, what are the key catalysts you're watching over 23 and 24? Terence Flynn: You know, as everyone probably knows, biopharma is a highly regulated industry. We have the FDA, the Food and Drug Administration here in the U.S., and we have the EMA in Europe. Those are the bodies that, you know, evaluate risk benefit of every therapy that's entering clinical trials and ultimately will reach the market. So this year we're expecting much of the focus for the gene editing companies to be broadly on regulatory progress. So again, this includes completion of regulatory filings here in the U.S. and Europe for the sickle cell disease drug that I mentioned before. And then something that's known as an IND filing. So essentially what companies are required to do is file that before they conduct clinical trials in humans in the U.S. There are companies that are pursuing this for hereditary angioedema and TTR amyloidosis. Those, if successful, would allow clinical trials to be conducted here in the U.S. and include U.S. patients. The other big thing we're watching is additional clinical data related to durability of efficacy. So, I think we've seen already with some of the gene therapies for hemophilia that we have durable efficacy out to five years, which is very exciting and promising. But the question is, will that last even longer? And how to think about gene therapy relative to gene editing on the durability side. And then lastly, I'd say safety. Obviously that's important for any therapy, but given some of the hurdles still that you mentioned, Matthew, that's obviously an important focus here as we look out over the longer term and something that the companies and the regulators are going to be following pretty closely. So again, as we think about the development of the field, one of the other key questions is access to patients. And so pricing reimbursement plays a key role here for any new therapy. There are some differences here, obviously, because we're talking about cures versus traditional chronic therapies. So maybe Matthew you could elaborate on that topic. Matthew Harrison: So as you think about these genetic medicines, the ones that we've seen approved have pretty broad price ranges, anywhere from a million to a few million dollars per patient, but you're talking about a potential cure here. And as I think about many of the chronic therapies, especially the more sophisticated ones that patients take, they can cost anywhere between tens of thousands and hundreds of thousands of dollars a year. So you can see over a decade or more of use how they can actually eclipse what seems like a very high upfront price of these genetic medicines. Now, one of the issues obviously, is that the way the payers are set up is different in different parts of the world. So in Europe, for example, there are single payer systems for the patient never switches between health insurance carriers. And so therefore you can capture that value very easily. In the U.S., obviously it's a much more complicated system, many people move between payers as they switch jobs, as you change from, you know, commercial payers when you're younger to a government payer as you move into Medicare. And so there needs to be a mechanism worked out on how to spread that value out. And so I think that's one of the things that will need to evolve. But, you know, it's a very exciting time here in genetic medicine. There's significant opportunity and I think we're on the cusp of really seeing a robust expansion of this field and leading to many potential therapies in the years to come. Terence Flynn: That's great, Matthew. Thanks so much for taking the time to talk today. Matthew Harrison: Great speaking with you, Terrence. Terence Flynn: As a reminder, if you enjoy Thoughts on the Market, please take a moment to rate and review us on Apple Podcasts app. It helps more people to find the show.